US Patent 9498512 Powerful MHC-class II peptides derived from survivin

Overview Structured Data Issues Contributors Activity

Is a

Patent

Date Filed

June 19, 2012

Date of Patent

November 22, 2016

Patent Application Number

13526597

Patent Citations Received

‌

US Patent 11826409 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

‌

US Patent 11885815 Reducing junction epitope presentation for neoantigens

‌

US Patent 11840562 Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

‌

US Patent 11666644 Peptide vaccines

‌

US Patent 11759507 Personalized immunotherapy against several neuronal and brain tumors

‌

US Patent 11833194 Peptides and combination of peptides for use in immunotherapy against various cancers

‌

US Patent 11786584 Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

‌

US Patent 11779606 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

‌

US Patent 11801264 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

‌

US Patent 11819518 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

•••

Patent Inventor Names

Peter Lewandrowski

Cecile Gouttefanges

Hans-Georg Rammensee

Stefan Stevanovic

Toni Weinschenk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9498512

Patent Primary Examiner

‌

Gerald R Ewoldt

Find more entities like US Patent 9498512 Powerful MHC-class II peptides derived from survivin

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.